NCT04998864 2026-04-16
Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier (BBB) Disruption in GBM Patients
InSightec
Completed
Clinical Trials
913 trialsNCT03451799 2026-04-15
Ketogenic Diet in Combination With Standard-of-care Radiation and Temozolomide for Patients With Glioblastoma
Cedars-Sinai Medical Center
Phase 1 Completed
NCT01872221 2026-04-14
STEMRI
Institut Claudius Regaud
Phase NA Completed
NCT02866747 2026-04-14
STERIMGLI
Institut Claudius Regaud
Phase 1/2 Completed
NCT04988750 2026-04-13
Evaluate the Safety and Preliminary Efficacy of the Combination of NaviFUS System With Re-irradiation for rGBM Patients
NaviFUS Corporation
Phase NA Completed
NCT04446416 2026-04-09
Efficacy and Safety of NaviFUS System add-on Bevacizumab (BEV) in Recurrent GBM Patients
NaviFUS Corporation
Phase NA Completed
NCT04730869 2026-04-09
Metabolic Therapy Program In Conjunction With Standard Treatment For Glioblastoma
Waikato Hospital
Phase NA Completed
NCT07497373 2026-04-03
JL15003
Jecho Biopharmaceuticals Co., Ltd.
Phase 1 Completed
NCT06650605 2026-03-31
CITADEL-123
Ariceum Therapeutics GmbH
Phase 1 Completed
NCT03194971 2026-03-30
NovoTTF Treatment Signatures in Glioblastoma Patients at Autopsy
Medical College of Wisconsin
Completed
NCT04471844 2026-03-30
EF-32
NovoCure Ltd.
Phase NA Completed
NCT07499141 2026-03-30
UFGAG
Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di Alessandria
Completed
NCT04019002 2026-03-27
Hyperpolarized Carbon-13 (13C) Pyruvate Imaging in Patients With Glioblastoma
University of California, San Francisco
Phase 1 Completed
NCT04801147 2026-03-27
DENDR1
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Phase 1/2 Completed
NCT02286167 2026-03-24
GLAD
Wake Forest University Health Sciences
Phase NA Completed
NCT03551249 2026-03-20
Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier (BBB) Disruption
InSightec
Phase NA Completed
NCT04417088 2026-03-20
Exablate Blood-Brain Barrier Disruption for the Treatment of rGBM in Subjects Undergoing Carboplatin Monotherapy
InSightec
Phase 1/2 Completed
NCT03475186 2026-03-13
Testing Ramipril to Prevent Memory Loss in People With Glioblastoma
Wake Forest University Health Sciences
Phase 2 Completed
NCT04044937 2026-03-11
UC-GlioFET
University of California, San Francisco
Phase 2 Completed
NCT04716699 2026-03-10
Systemic and Local Levels of Lidocaine During Surgery for the Removal of Glioblastoma
University of California, Davis
Phase 1 Completed
NCT04391595 2026-03-06
LY3214996 Plus Abemaciclib in Recurrent Glioblastoma Patients
St. Joseph's Hospital and Medical Center, Phoenix
Phase EARLY_PHASE1 Completed
NCT05431348 2026-03-04
ERROR
Maastricht Radiation Oncology
Completed
NCT04238819 2026-03-02
A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma
Eli Lilly and Company
Phase 1/2 Completed
NCT06665724 2026-02-27
Clinical Trial Evaluating Safety of 5-Aminolevulinic Acid (5-ALA) Combined With CV01 Delivery of Ultrasound for Sonodynamic Therapy (SDT) in Patients With Newly Diagnosed High-Grade Glioma (HGG) Prior to Resection and Standard Adjuvant Therapy (ALA SDT GLIOMA 401)
Universität Münster
Phase 1 Completed
NCT02669173 2026-02-23
Capecitabine + Bevacizumab in Patients With Recurrent Glioblastoma
Case Comprehensive Cancer Center
Phase 1 Completed
NCT05938387 2026-02-18
Safety and Tolerability of CVGBM in Adults With Newly Diagnosed MGMT-Unmethylated Glioblastoma or Astrocytoma
CureVac
Phase 1 Completed
NCT03529448 2026-02-12
GEINOCANN
Grupo Español de Investigación en Neurooncología
Phase 1/2 Completed
NCT03681028 2026-02-12
Feasibility of Individualized Therapy for Recurrent Glioblastoma
University of California, San Francisco
Phase 1 Completed
NCT04822688 2026-02-10
Analysis of Cell Count, Viability, and Immunogenicity of Discarded Newly Diagnosed Glioblastoma Tissue or Solid Tumor Tissues
Thomas Jefferson University
Completed
NCT03048240 2026-02-05
INDYGO
University Hospital, Lille
Phase NA Completed
NCT04440358 2026-01-20
Exablate Blood-Brain Barrier Disruption With Carboplatin for the Treatment of rGBM
InSightec
Phase 1/2 Completed
NCT06095375 2026-01-09
REGOMA-2
Istituto Oncologico Veneto IRCCS
Phase 1 Completed
NCT04295759 2026-01-05
INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas
Pediatric Brain Tumor Consortium
Phase 1 Completed
NCT02617745 2026-01-02
GLIOPLAK
Centre Henri Becquerel
Phase 2 Completed
NCT02709226 2025-12-31
Dose Escalation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT06625047 2025-12-31
Comparing Telehealth and In-person Assessments in Glioma Patients Receiving Oral Chemotherapy
Mayo Clinic
Phase 4 Completed
NCT04474353 2025-12-26
Study of Tumor Treating Fields With Hypofractionated Chemoradiotherapy in Newly Diagnosed Glioblastoma
Stanford University
Phase 1 Completed
NCT05735171 2025-12-24
SupraGlio-AI
Hospital del Rio Hortega
Phase NA Completed
NCT04566185 2025-12-18
EVA DOPA
Centre Hospitalier Universitaire de Nīmes
Phase NA Completed
NCT06451042 2025-12-18
FET-TREAT
Sunnybrook Health Sciences Centre
Completed
NCT02902757 2025-12-17
FDG PET/CT in Monitoring Very Early Therapy Response in Patients With Glioblastoma
Jonsson Comprehensive Cancer Center
Phase NA Completed
NCT05432375 2025-12-10
Study of Tinostamustine for Adjuvant Treatment of Glioblastoma
Mundipharma Research Limited
Phase EARLY_PHASE1 Completed
NCT04391062 2025-12-05
DOSINDYGO
University Hospital, Lille
Phase 2 Completed
NCT04116658 2025-11-28
ROSALIE
Enterome
Phase 1/2 Completed
NCT03224104 2025-11-26
STEAM
European Organisation for Research and Treatment of Cancer - EORTC
Phase 1 Completed
NCT01582269 2025-11-24
A Study in Recurrent Glioblastoma (GB)
Eli Lilly and Company
Phase 2 Completed
NCT03532295 2025-11-21
Retifanlimab and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas
Washington University School of Medicine
Phase 2 Completed
NCT03797326 2025-11-17
LEAP-005
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT03746080 2025-11-14
Whole Brain Radiation Therapy With Standard Temozolomide Chemo-Radiotherapy and Plerixafor in Treating Patients With Glioblastoma
Stanford University
Phase 2 Completed
NCT04826393 2025-10-22
ASP8374 + Cemiplimab in Recurrent Glioma
Dana-Farber Cancer Institute
Phase 1 Completed